アルツハイマー病治療薬市場：薬剤クラス別、流通チャネル別-2024-2030年の世界予測

アルツハイマー病治療薬市場規模は2023年に43億米ドルと推計され、2024年には47億4,000万米ドルに達し、CAGR 10.10%で2030年には84億5,000万米ドルに達すると予測されます。

世界のアルツハイマー病治療薬市場

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはアルツハイマー病治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、アルツハイマー病治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-アルツハイマー病治療薬市場の市場規模および予測は？

2-アルツハイマー病治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-アルツハイマー病治療薬市場における技術動向と規制の枠組みは？

4-アルツハイマー病治療薬市場における主要ベンダーの市場シェアは？

5-アルツハイマー病治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加と疾病負担の増大
    • アルツハイマー病治療に対する意識の高まり
    • アルツハイマー病治療のための費用対効果の高い薬の入手可能性
  • 抑制要因
    • 医薬品開発のための研究開発活動には高額な費用がかかる
  • 機会
    • アルツハイマー病の治療の進歩
    • オンライン薬局の導入とオンラインチャネルがもたらすメリット
  • 課題
    • アルツハイマー病治療薬に伴う副作用
• 市場セグメンテーション分析
• 市場動向分析
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み

第6章 アルツハイマー病治療薬市場薬剤クラス別

• コリン作動性
• 配合剤
• メマンチン

第7章 アルツハイマー病治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 南北アメリカのアルツハイマー病治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のアルツハイマー病治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのアルツハイマー病治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

• 主要な企業プロファイル
  • AB Science
  • AC Immune SA
  • AstraZeneca PLC
  • Avanir Pharmaceuticals Inc. by Otsuka Pharmaceutical, Inc.
  • Biogen Inc.
  • Corium Inc.
  • Eisai Co., Ltd.
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Luye Pharma Group
  • Novartis AG
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Limited
  • TauRx Therapeutics Ltd.
  • Teva Pharmaceutical Industries Ltd.
• 主要な製品ポートフォリオ

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. ALZHEIMER'S DISEASE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ALZHEIMER'S DISEASE DRUGS MARKET DYNAMICS
• FIGURE 7. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 8. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 10. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ALZHEIMER'S DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
• FIGURE 20. ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

• TABLE 1. ALZHEIMER'S DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 6. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COMBINED DRUG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 10. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. CANADA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. CHINA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. INDIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. ITALY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. POLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. POLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. QATAR ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM ALZHEIMER'S DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ALZHEIMER'S DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
• TABLE 100. ALZHEIMER'S DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. ALZHEIMER'S DISEASE DRUGS MARKET LICENSE & PRICING

[196 Pages Report] The Alzheimer's Disease Drugs Market size was estimated at USD 4.30 billion in 2023 and expected to reach USD 4.74 billion in 2024, at a CAGR 10.10% to reach USD 8.45 billion by 2030.

Global Alzheimer's Disease Drugs Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer's Disease Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer's Disease Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer's Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AB Science, AC Immune SA, AstraZeneca PLC, Avanir Pharmaceuticals Inc. by Otsuka Pharmaceutical, Inc., Biogen Inc., Corium Inc., Eisai Co., Ltd., Grifols, S.A., H. Lundbeck A/S, Luye Pharma Group, Novartis AG, Siemens Healthineers AG, Sun Pharmaceutical Industries Limited, TauRx Therapeutics Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Alzheimer's Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Class
  • Cholinergic
  • Combined Drug
  • Memantine
• Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alzheimer's Disease Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer's Disease Drugs Market?

3. What are the technology trends and regulatory frameworks in the Alzheimer's Disease Drugs Market?

4. What is the market share of the leading vendors in the Alzheimer's Disease Drugs Market?

5. Which modes and strategic moves are suitable for entering the Alzheimer's Disease Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Alzheimer's Disease Drugs Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing geriatric population and rising disease burden
    • 5.1.1.2. Rising awareness regarding Alzheimer's treatment
    • 5.1.1.3. Availability of cost-effective medicine for the treatment of Alzheimer
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of R&D activities for drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in the treatment of Alzheimer's diseases
    • 5.1.3.2. Adoption of online pharmacies and advantages offered by online channels
  • 5.1.4. Challenges
    • 5.1.4.1. Side effect associated with Alzheimer's drugs
• 5.2. Market Segmentation Analysis
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. Alzheimer's Disease Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Cholinergic
• 6.3. Combined Drug
• 6.4. Memantine

7. Alzheimer's Disease Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Pharmacy
• 7.4. Retail Pharmacy

8. Americas Alzheimer's Disease Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Alzheimer's Disease Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Alzheimer's Disease Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

• 12.1. Key Company Profiles
  • 12.1.1. AB Science
  • 12.1.2. AC Immune SA
  • 12.1.3. AstraZeneca PLC
  • 12.1.4. Avanir Pharmaceuticals Inc. by Otsuka Pharmaceutical, Inc.
  • 12.1.5. Biogen Inc.
  • 12.1.6. Corium Inc.
  • 12.1.7. Eisai Co., Ltd.
  • 12.1.8. Grifols, S.A.
  • 12.1.9. H. Lundbeck A/S
  • 12.1.10. Luye Pharma Group
  • 12.1.11. Novartis AG
  • 12.1.12. Siemens Healthineers AG
  • 12.1.13. Sun Pharmaceutical Industries Limited
  • 12.1.14. TauRx Therapeutics Ltd.
  • 12.1.15. Teva Pharmaceutical Industries Ltd.
• 12.2. Key Product Portfolio

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing